Search

Mark Allen Schenerman

from Reisterstown, MD
Age ~66
Get Report
Also known as:
Mark A Schenerman
Phone and address:
1 Cornfield Ct, Reisterstown, MD 21136
(410) 526-2723
Related to:
Linda Diane Henley, 70Christopher Louis Dollins, 47Marilyn ShawRosemary Presnell, 58Ray ShawJeffery Shaw, 68
Connected to:
Kendra L Schenerlein, 43William V Schenewerk, 83Megan E Schenfeld, 40Andrew J Schenfield, 47Michelle Schengber, 57John A Schengel, 77Peter J Schengrund, 82Timothy J Schengrund, 58Amber Schenk, 72Anne Schenk, 65

Mark Schenerman Phones & Addresses

  • 1 Cornfield Ct, Reisterstown, MD 21136 (410) 526-2723
  • Pikesville, MD
  • Fayetteville, NY
  • Syracuse, NY

Education

Degree: High school graduate or higher

Resumes

Resumes

Mark Schenerman Photo 1

Senior Advisor For Cmc Science And Technology And Strategy

View page
Location:
1 Medimmune Way, Gaithersburg, MD 20877
Industry:
Biotechnology
Work:
Novavax
Senior Advisor For Cmc Science and Technology and Strategy
Johns Hopkins University Pharmacology and Molecular Medicines
Adjunct Professor
University of Maryland Baltimore County
Professor
Cmc Biotech-Mas Consulting
President
Medimmune Apr 1, 2016 - May 2017
Vp, Regulatory and External Sciences
Education:
Cornell University 1986 - 1988
University of Florida 1981 - 1986
Doctorates, Doctor of Philosophy, Molecular Biology, Biochemistry University of Maryland - Baltimore 1979 - 1980
Bachelors University of Maryland Baltimore County 1976 - 1979
Skills:
Biopharmaceuticals
Assay Development
Analytical Chemistry
Biotechnology
Life Sciences
Protein Purification
Gmp
Pharmaceutical Industry
Clinical Development
Monoclonal Antibodies
Validation
Protein Chemistry
Technology Transfer
Sop
Mark Schenerman Photo 2

Mark Schenerman

View page

Publications

Us Patents

Antibodies Against And Methods For Producing Vaccines For Respiratory Syncytial Virus

View page
US Patent:
7700720, Apr 20, 2010
Filed:
Sep 21, 2005
Appl. No.:
11/230593
Inventors:
Guillermo Tous - East Windsor NJ, US
Mark Schenerman - Reisterstown MD, US
Jose Casas-Finet - Gaithersburg MD, US
Ziping Wei - North Potomac MD, US
David Pfarr - Darnestown MD, US
Assignee:
MedImmune, LLC - Gaithersburg MD
International Classification:
A61K 39/155
C07K 14/115
C07K 19/00
US Classification:
530325, 4241841, 4241851, 4241921, 4242111, 530300
Abstract:
The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

Macromolecules Comprising A Thioether Cross-Link

View page
US Patent:
7786273, Aug 31, 2010
Filed:
Mar 14, 2006
Appl. No.:
11/375810
Inventors:
Guillermo I. Tous - East Windsor NJ, US
Mark Schenerman - Reisterstown MD, US
Ziping Wei - North Potomac MD, US
Assignee:
Medimmune, LLC - Gaithersburg MD
International Classification:
C07K 16/00
C07K 16/08
C07K 1/10
A61K 39/395
A61K 39/42
US Classification:
5303881, 530402, 5303873, 5303889, 4241331, 4241391, 4241411, 4241471
Abstract:
The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention.

Vitro Assay For Measuring The Immunogenicity Of A Vaccine

View page
US Patent:
20020160358, Oct 31, 2002
Filed:
Sep 18, 2001
Appl. No.:
09/954044
Inventors:
Mark Schenerman - Reisterstown MD, US
Robert Strouse - Derwood MD, US
JoAnn Suzich - Washington Grove MD, US
Wendy White - Germantown MD, US
Assignee:
MedImmune, Inc. - Gaithersburg MD
International Classification:
C12Q001/70
G01N033/53
G01N033/542
A61K039/395
C12N005/06
C12N005/16
US Classification:
435/005000, 435/007900, 435/345000, 435/343100, 435/343200, 435/343000, 424/130100
Abstract:
The present invention provides an assay for measuring the immunogenicity of a vaccine, wherein the vaccine contains an epitope having a conformation associated with an immunogenically active form of the vaccine and a fragment having a conformation associated with an immunogenically inactive form of the vaccine, wherein the method includes exposing a sample of the vaccine to a first ligand capable of binding to the epitope in the conformation associated with the immunogenically active form of the vaccine and a second ligand capable of binding to the fragment in the conformation associated with the immunogenically inactive form of the vaccine and measuring the amount of first ligand bound to the vaccine sample and the amount of the second ligand bound to the vaccine sample.

Stabilized Glycoproteins

View page
US Patent:
20040191265, Sep 30, 2004
Filed:
Jan 5, 2004
Appl. No.:
10/751744
Inventors:
Mark Schenerman - Reisterstown MD, US
Jose Casas-Finet - Gaithersburg MD, US
Jinhua Feng - North Potomac MD, US
Guillermo Tous - Gaithersburg MD, US
International Classification:
A61K039/00
A61K039/38
US Classification:
424/184100
Abstract:
The present invention provides stabilized immunoglobulin molecules that have increased storage stability and/or in vivo half-lives due to the mutation of one or more amino acids that would otherwise render the immunoglobulin molecules susceptible to degradation. In a preferred embodiment, the stabilized immunoglobulins of the invention have mutations at the heavy chain constant domain hinge region. Such stabilized immunoglobulin molecules, i.e., immunoglobulin molecules with increased storage stability have one or more of the following advantages they are more readily transported and/storable for longer periods and/or less stringent conditions than non-stabilized counterparts; that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such stabilized molecules.

Antibody Formulations Having Optimized Aggregation And Fragmentation Profiles

View page
US Patent:
20070110757, May 17, 2007
Filed:
Jun 23, 2006
Appl. No.:
11/473537
Inventors:
Ziping Wei - North Potomac MD, US
Guillermo Tous - East Windsor NJ, US
Mark Schenerman - Reisterstown MD, US
Christian Allan - Brookeville MD, US
International Classification:
A61K 39/42
C07K 16/10
US Classification:
424159100, 530388300
Abstract:
The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.

Macromolecules Comprising A Thioether Cross-Link

View page
US Patent:
20090030187, Jan 29, 2009
Filed:
Mar 14, 2006
Appl. No.:
11/908601
Inventors:
Guillermo I. Tous - East Windsor NJ, US
Mark Schenerman - Reisterstown MD, US
Ziping Wei - North Potomac MD, US
International Classification:
C07K 16/00
C07K 16/08
C07K 16/18
C07K 16/24
US Classification:
5303873, 5303871, 5303881, 5303894, 5303896, 5303892
Abstract:
The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention.

Antibodies Against And Methods For Producing Vaccines For Respiratory Syncytial Virus

View page
US Patent:
20100278852, Nov 4, 2010
Filed:
Mar 5, 2010
Appl. No.:
12/718476
Inventors:
Guillermo TOUS - East Windsor NJ, US
Mark SCHENERMAN - Reisterstown MD, US
Jose CASAS-FINET - Gaithersburg MD, US
Ziping WEI - North Potomac MD, US
David PFARR - Darnestown MD, US
Assignee:
MEDIMMUNE, LLC - Gaithersburg MD
International Classification:
C12Q 1/70
A61K 39/155
C07K 14/135
A61P 31/14
US Classification:
4241861, 530325, 435 5
Abstract:
The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

Antibody Formulations Having Optimized Aggregation And Fragmentation Profiles

View page
US Patent:
20100278929, Nov 4, 2010
Filed:
Jan 19, 2010
Appl. No.:
12/689432
Inventors:
Ziping Wei - North Potamac MD, US
Guillermo Tous - East Windsor NJ, US
Mark Schenerman - Reisterstown MD, US
Christian B. Allan - Brookeville MD, US
Assignee:
Medlmmune, LLC - Gaithersburg MD
International Classification:
A61K 9/14
A61K 39/395
A61P 31/14
A61K 39/42
A61P 11/00
US Classification:
424499, 4241301, 4241591
Abstract:
The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.
Control profile
Mark Allen Schenerman from Reisterstown, MD, age ~66 Get Report